Overview

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Health

Status:
Completed

Trial end date:
2016-09-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy preterm infants.

Phase:

Phase 1

Details

Lead Sponsor:

MedImmune LLC

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoglobulins